drugset / Trial / NCT02183441
Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
Study to investigate the effect of the P-gp and cytochrome P450 (CYP) 3A4 inhibitor ritonavir on the pharmacokinetics of BI 1356
Timeline
- Start
- 2008-04
- Primary completion
- 2008-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Small molecule | 5 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 200 mg | Oral |
Indications
No indication recorded.